This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

The Deal: Akorn Acquires Hi-Tech Pharmacal for $540M

NEW YORK (TheStreet) -- Specialty pharmaceuticals firm Akorn (AKRX) said Tuesday it would acquire Hi-Tech Pharmacal (HITK) in a $540 million cash deal that would expand the maker of eye-care products into new areas.

Terms of the deal call for Akorn to pay $43.50 per share in cash for Hi-Tech, a premium of 23.5% to the Amityville, N.Y.-based target's Aug. 26 close. The deal values Hi-Tech's equity at $640 million, with Akorn also taking control of Hi-Tech's $100.6 million in cash and cash equivalents.

Hi-Tech is a developer and manufacturer of generic and branded prescription and over-the-counter products including a range of oral solutions, topical ointments and creams, nasal sprays, otics, sterile ophthalmics and sterile ointment and gels products. The company's brands include Diabetic Tussin, DiabetiDerm, DiabetiSweet, Zostrix, Nasal Ease and Sinus Buster.

Akorn, of Lake Forest, Ill., is best known as a maker of generic eye-care products. The company said in a statement that the deal would create a more diversified generics manufacturer, and expand its pipeline. Akorn currently has 57 new drug applications filed with the Food and Drug Administration. Hi-Tech has 18 applications pending.

The buyer said it believes it can extract upwards of $20 million in annual savings within 12 months and create a combined company with more than $500 million in sales.

"The portfolio of Hi-Tech products is a great strategic fit to our currently marketed products as it diversifies our offering to our retail customers beyond ophthalmics," said Akorn CEO Raj Rai. "In addition, we are excited about Hi-Tech's product pipeline which would further enhance growth opportunities for the combined platform."

Akorn said it intends to fund the deal via a combination of Hi-Tech cash assumed and a $600 million term loan to be provided by JPMorgan Chase.

JPMorgan Securities is acting as financial adviser to Akorn, with a Kirkland & Ellis team of Keith Crow, Joshua Zachariah and David Fox joining with attorneys with Polsinelli PC to provide legal advice.

Hi-Tech was advised by Nomura Securities International, Arent Fox and Tashlik Goldwyn Crandell Levy.

--Written by Lou Whiteman in New York

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,086.63 -26.91 -0.16%
S&P 500 1,987.01 +3.48 0.18%
NASDAQ 4,473.6970 +17.6810 0.40%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs